A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

While there’s no cure for multiple sclerosis ... No stem cell therapies for MS are currently approved by the FDA. According to one research review, mesenchymal stem cell (MSC) therapy may ...

In MS, immune system cells mistakenly attack myelin. With stem cell treatment, doctors use chemotherapy to destroy these existing immune cells. Then, they introduce the new stem cells, which are ...

May 28, 2024 — Researchers have demonstrated how B cells infected with the Epstein ... Potential New Drug Treatment for Multiple Sclerosis Dec. 8, 2023 — Pre-clinical studies using a small ...

The following is a summary of “Chronic graft-versus-host disease myelitis successfully treated with rituximab,” published in ...

Neuraxpharm Ireland, part of Neuraxpharm Group, a leading European speciality pharmaceutical company focused on the treatment ...

Researchers have made more advancements in multiple sclerosis in the last five years than in the previous 70 years. Knowing ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...